Mvabea

Modified Vaccinia Ankara – Bavarian Nordic Virus Encoding The Ebola Virus Zaire Mayinga Strain Glyco, the active ingredient in Mvabea, is a vaccine presented as a vaccine for intramuscular use. It is intended to prevent Ebola virus disease caused by the Zaire ebolavirus in individuals at risk of exposure.

GNH USA supplies Mvabea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to EU quality standards and provides cold‑chain logistics for biologic products.

Mvabea is used as a prophylactic vaccine targeting the Ebola virus family.

Ebola virus disease (Zaire ebolavirus): Induces protective immunity to prevent infection in at‑risk populations. Healthcare workers in outbreak zones: Provides pre‑exposure protection to reduce occupational risk. Contacts of confirmed cases: Offers post‑exposure prophylaxis to limit secondary transmission.

Common and serious adverse reactions have been reported following intramuscular administration of Mvabea.

Common Side Effects: - Injection site pain or tenderness. - Redness or swelling at the injection site. - Low‑grade fever. - Headache. - Fatigue or malaise. - Muscle aches.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Guillain‑Barré syndrome. - Myocarditis or pericarditis. - Neurological events such as encephalitis. - Thrombocytopenia.

Prior to vaccination, several safety considerations should be observed.

Allergy screening: Verify no known hypersensitivity to vaccine components before administration. Immunocompromised patients: Assess risk as immune response may be reduced. Pregnancy: Use only if the potential benefit justifies the potential risk; data are limited. Concurrent immunosuppressive therapy: May diminish vaccine efficacy; consider timing of administration. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines can interact with other medical products, requiring attention to timing and patient condition.

Major Interactions (Avoid): - Live viral vaccines administered concurrently: May interfere with immune response to either product. - Severe immunodeficiency (e.g., untreated HIV with CD4 <200): Vaccine may be contraindicated.

Moderate Interactions (Monitor Closely): - Immunosuppressive drugs (e.g., corticosteroids, chemotherapy): May reduce immunogenicity; consider spacing doses. - Antipyretics taken prophylactically: May blunt the desired immune response; use only for symptom relief after vaccination. - Blood products given within 4 weeks: Could affect vaccine efficacy.